STOK
Stoke Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$28.43
−1.73%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$28.87
From 52W high−25.87%
Volume1.48M
Market cap$1.83B
P/E (TTM)—
P/S (TTM)66.5x
Div yield—
Key dataSep 18, 2026
Open
$28.87
From 52W high
−25.87%
Volume
1.48M
Market cap
$1.83B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−7.5x
P/E (TTM)
—
RSI (14)
38.5
MomentumView details →
1D Return
−1.73%
YTD Return
−10.47%
SummaryUpdated Jun 1, 2026
Stoke Therapeutics, Inc. (NASDAQ:STOK) is an early-stage biopharmaceutical company founded in 2014 and headquartered in Bedford, Massachusetts. Originally incorporated as ASOthera Pharmaceuticals, Inc., the company changed its name to Stoke Therapeutics in May 2016 and went public in June 2019. Stoke focuses on developing novel antisense oligonucleotide medicines to treat severe genetic diseases by addressing their underlying molecular causes rather than just managing symptoms.
Similar companies
Latest newsMore news →
Bank of America Corp DE increased its stake in Stoke Therapeutics, Inc. by 163.4% during the first quarter, buying an additional 336,931 shares, according to a recent SEC filing.32d agoStoke Therapeutics announced that its Phase III EMPEROR study of zorevunersen in Dravet syndrome patients remains on track for a data readout in Q3 2027, following completion of enrollment ahead of the planned rolling NDA submission.48d agoStoke Therapeutics reported its financial results for the second quarter ended June 30, 2026, and provided business updates including progress of its global Phase program for zorevunersen in Dravet syndrome.48d ago